Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Daclatasvir> ?p ?o }
Showing triples 1 to 75 of
75
with 100 triples per page.
- Daclatasvir abstract "Daclatasvir (USAN, formerly BMS-790052, trade name Daklinza) is a drug for the treatment of hepatitis C (HCV). It was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daklinza gained its FDA approval on July 24, 2015 in the United States; it is approved for Hepatitis C genotype 3 infections. A generic version of daclatasvir is expected to be approved in India before the end of 2015.Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.".
- Daclatasvir iupacName "Methyl[(2S)-1-{(2S)-2-[4-(4’-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-4-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate".
- Daclatasvir thumbnail Daclatasvir.svg?width=300.
- Daclatasvir wikiPageID "36008851".
- Daclatasvir wikiPageLength "6645".
- Daclatasvir wikiPageOutDegree "17".
- Daclatasvir wikiPageRevisionID "696886106".
- Daclatasvir wikiPageWikiLink Asunaprevir.
- Daclatasvir wikiPageWikiLink Bristol-Myers_Squibb.
- Daclatasvir wikiPageWikiLink Category:Biphenyls.
- Daclatasvir wikiPageWikiLink Category:Carbamates.
- Daclatasvir wikiPageWikiLink Category:Imidazoles.
- Daclatasvir wikiPageWikiLink Category:NS5A_inhibitors.
- Daclatasvir wikiPageWikiLink Category:Pyrrolidines.
- Daclatasvir wikiPageWikiLink Category:World_Health_Organization_essential_medicines.
- Daclatasvir wikiPageWikiLink Drug_development.
- Daclatasvir wikiPageWikiLink Health_system.
- Daclatasvir wikiPageWikiLink Hepatitis_C.
- Daclatasvir wikiPageWikiLink NS5A.
- Daclatasvir wikiPageWikiLink Pegylated_interferon.
- Daclatasvir wikiPageWikiLink Ribavirin.
- Daclatasvir wikiPageWikiLink Sofosbuvir.
- Daclatasvir wikiPageWikiLink United_States_Adopted_Name.
- Daclatasvir wikiPageWikiLink WHO_Model_List_of_Essential_Medicines.
- Daclatasvir wikiPageWikiLinkText "Daclatasvir".
- Daclatasvir wikiPageWikiLinkText "Daklinza (daclatasvir)".
- Daclatasvir wikiPageWikiLinkText "daclatasvir".
- Daclatasvir imagefile "Daclatasvir.svg".
- Daclatasvir imagesize "250".
- Daclatasvir iupacname "Methyl [-1-{-2-[4--1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate".
- Daclatasvir othernames "BMS-790052; NATDAC".
- Daclatasvir wikiPageUsesTemplate Template:Antiinfective-drug-stub.
- Daclatasvir wikiPageUsesTemplate Template:Cascite.
- Daclatasvir wikiPageUsesTemplate Template:Chembox.
- Daclatasvir wikiPageUsesTemplate Template:Chembox_Hazards.
- Daclatasvir wikiPageUsesTemplate Template:Chembox_Identifiers.
- Daclatasvir wikiPageUsesTemplate Template:Chembox_Pharmacology.
- Daclatasvir wikiPageUsesTemplate Template:Chembox_Properties.
- Daclatasvir wikiPageUsesTemplate Template:Ebicite.
- Daclatasvir wikiPageUsesTemplate Template:Fact.
- Daclatasvir wikiPageUsesTemplate Template:RNA_antivirals.
- Daclatasvir wikiPageUsesTemplate Template:Reflist.
- Daclatasvir subject Category:Biphenyls.
- Daclatasvir subject Category:Carbamates.
- Daclatasvir subject Category:Imidazoles.
- Daclatasvir subject Category:NS5A_inhibitors.
- Daclatasvir subject Category:Pyrrolidines.
- Daclatasvir subject Category:World_Health_Organization_essential_medicines.
- Daclatasvir hypernym Drug.
- Daclatasvir type ChemicalCompound.
- Daclatasvir type ChemicalSubstance.
- Daclatasvir type Drug.
- Daclatasvir type Amide.
- Daclatasvir type Carbamate.
- Daclatasvir type Diazole.
- Daclatasvir type Ester.
- Daclatasvir type Inhibitor.
- Daclatasvir type ChemicalObject.
- Daclatasvir type Thing.
- Daclatasvir type Q11173.
- Daclatasvir comment "Daclatasvir (USAN, formerly BMS-790052, trade name Daklinza) is a drug for the treatment of hepatitis C (HCV). It was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daklinza gained its FDA approval on July 24, 2015 in the United States; it is approved for Hepatitis C genotype 3 infections. A generic version of daclatasvir is expected to be approved in India before the end of 2015.Daclatasvir inhibits the HCV nonstructural protein NS5A.".
- Daclatasvir label "Daclatasvir".
- Daclatasvir sameAs Q5207712.
- Daclatasvir sameAs Daclatasvir.
- Daclatasvir sameAs Daclatasvir.
- Daclatasvir sameAs ダクラタスビル.
- Daclatasvir sameAs Daklataswir.
- Daclatasvir sameAs m.0j_6hxg.
- Daclatasvir sameAs Даклатасвир.
- Daclatasvir sameAs Daklatasvir.
- Daclatasvir sameAs Daklatasvir.
- Daclatasvir sameAs Q5207712.
- Daclatasvir wasDerivedFrom Daclatasvir?oldid=696886106.
- Daclatasvir depiction Daclatasvir.svg.
- Daclatasvir isPrimaryTopicOf Daclatasvir.